| A Study of HFB301001 in Adult Patients With Advanced Solid Tumors (NCT05229601) | HiFiBiO Therapeutics | 2022-04-20 |
| A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine Carcinosarcoma (NCT05147558) | Memorial Sloan Kettering Cancer Center | 2021-12-23 |
| The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib) (NCT03694262) | Medical College of Wisconsin | 2019-07-19 |
| Web-Based Coping and Communication Skills Intervention in Improving Psychological Adaptation in Patients With Gynecological Cancer (NCT03902379) | Rutgers, The State University of New Jersey | 2016-07-27 |
| Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer (NCT01367301) | Albert Einstein College of Medicine | 2011-07-08 |
| Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer (NCT01247571) | National Cancer Institute (NCI) | 2011-01-01 |
| Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer (NCT01168232) | National Cancer Institute (NCI) | 2010-09-07 |
| Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus (NCT01061606) | National Cancer Institute (NCI) | 2010-01-01 |
| Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer (NCT01010126) | National Cancer Institute (NCI) | 2009-09-08 |
| Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer (NCT00954174) | GOG Foundation | 2009-08-17 |
| Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma (NCT00687687) | Sanofi | 2008-05-01 |
| Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer (NCT00478426) | National Cancer Institute (NCI) | 2007-04-30 |
| Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma (NCT00390234) | National Cancer Institute (NCI) | 2006-09-01 |
| Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma (NCT00245102) | National Cancer Institute (NCI) | 2005-09-01 |
| Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer (NCT00114218) | Gynecologic Oncology Group | 2005-03-01 |
| Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer (NCT00238121) | National Cancer Institute (NCI) | 2005-02-01 |
| Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer (NCT00075400) | National Cancer Institute (NCI) | 2004-01-01 |
| Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus (NCT00025506) | National Cancer Institute (NCI) | 2001-09-01 |